Matching articles for "Kevzara"

Sarilumab (Kevzara) for Polymyalgia Rheumatica

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024;  (Issue 1702)
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids...
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi/Regeneron) for treatment of polymyalgia rheumatica (PMR) in adults who had an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. Sarilumab is the first biologic drug to be approved for treatment of PMR; it was previously approved for treatment of rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 | Show Full IntroductionHide Full Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • November 15, 2021;  (Issue 1637)
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • November 15, 2021;  (Issue 1637)
...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e187-9 | Show Full IntroductionHide Full Introduction

Flowchart: Rheumatoid Arthritis Treatment (online only)

   
The Medical Letter on Drugs and Therapeutics • November 15, 2021;  (Issue 1637)
...
View the Flowchart: Rheumatoid Arthritis Treatment
Med Lett Drugs Ther. 2021 Nov 15;63(1637):e1 | Show Full IntroductionHide Full Introduction

Some Drugs for COVID-19

   
The Medical Letter on Drugs and Therapeutics • April 6, 2020;  (Issue 1595)
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in...
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50 | Show Full IntroductionHide Full Introduction

Table: Treatments Considered for COVID-19 (Archived) (online only)

   
The Medical Letter on Drugs and Therapeutics • April 6, 2020;  (Issue 1595)
...
View the Table: Treatments Considered for COVID-19
Med Lett Drugs Ther. 2020 Apr 6;62(1595):e1-289 | Show Full IntroductionHide Full Introduction

Some Drugs for COVID-19

   
The Medical Letter on Drugs and Therapeutics • April 6, 2020;  (Issue 1919)
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in...
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Med Lett Drugs Ther. 2020 Apr 6;62(1919):1 | Show Full IntroductionHide Full Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • July 30, 2018;  (Issue 1552)
Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally...
Disease-modifying antirheumatic drugs (DMARDs) are used for initial treatment of rheumatoid arthritis (RA) to achieve clinical remission and prevent irreversible joint damage (see Table 1). DMARDs generally do not have an immediate analgesic effect, but over time they can control symptoms and have been shown to delay and possibly stop progression of the disease. Methotrexate (Trexall, and others) is generally the drug of choice; it can be used for patients with low, moderate, or high disease activity. For mild disease, some clinicians prefer to start with hydroxychloroquine (Plaquenil, and generics) and/or sulfasalazine (Azulfidine, and others).
Med Lett Drugs Ther. 2018 Jul 30;60(1552):123-8 | Show Full IntroductionHide Full Introduction

Expanded Table: Biologic Agents for Rheumatoid Arthritis (online only)

   
The Medical Letter on Drugs and Therapeutics • July 30, 2018;  (Issue 1552)
...
View Expanded Table: Biologic Agents for Rheumatoid Arthritis
Med Lett Drugs Ther. 2018 Jul 30;60(1552):e130-4 | Show Full IntroductionHide Full Introduction

Sarilumab (Kevzara) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • August 14, 2017;  (Issue 1527)
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second...
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab (Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6 inhibitor to be approved for this indication; tocilizumab (Actemra) was approved earlier.
Med Lett Drugs Ther. 2017 Aug 14;59(1527):134-6 | Show Full IntroductionHide Full Introduction